SG11202100934PA - Muscle targeting complexes and uses thereof for treating dystrophinopathies - Google Patents
Muscle targeting complexes and uses thereof for treating dystrophinopathiesInfo
- Publication number
- SG11202100934PA SG11202100934PA SG11202100934PA SG11202100934PA SG11202100934PA SG 11202100934P A SG11202100934P A SG 11202100934PA SG 11202100934P A SG11202100934P A SG 11202100934PA SG 11202100934P A SG11202100934P A SG 11202100934PA SG 11202100934P A SG11202100934P A SG 11202100934PA
- Authority
- SG
- Singapore
- Prior art keywords
- muscle targeting
- targeting complexes
- dystrophinopathies
- treating
- treating dystrophinopathies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/02—Pentosyltransferases (2.4.2)
- C12Y204/02008—Hypoxanthine phosphoribosyltransferase (2.4.2.8)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862714031P | 2018-08-02 | 2018-08-02 | |
US201962855766P | 2019-05-31 | 2019-05-31 | |
PCT/US2019/044949 WO2020028832A1 (en) | 2018-08-02 | 2019-08-02 | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202100934PA true SG11202100934PA (en) | 2021-02-25 |
Family
ID=69232665
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202100934PA SG11202100934PA (en) | 2018-08-02 | 2019-08-02 | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
Country Status (11)
Country | Link |
---|---|
US (6) | US20210308273A1 (en) |
EP (1) | EP3829595A4 (en) |
JP (1) | JP2021532831A (en) |
KR (1) | KR20210081322A (en) |
CN (1) | CN112955153A (en) |
AU (1) | AU2019312692A1 (en) |
CA (1) | CA3108282A1 (en) |
IL (1) | IL280527A (en) |
MX (1) | MX2021001281A (en) |
SG (1) | SG11202100934PA (en) |
WO (1) | WO2020028832A1 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210081324A (en) | 2018-08-02 | 2021-07-01 | 다인 세라퓨틱스, 인크. | Muscle targeting complexes and their use for treating facioscapulohumeral muscular dystrophy |
US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
JP2022513482A (en) | 2018-12-21 | 2022-02-08 | アビディティー バイオサイエンシーズ,インク. | Anti-transferrin receptor antibody and its use |
KR20220118459A (en) * | 2019-12-19 | 2022-08-25 | 니뽄 신야쿠 가부시키가이샤 | Antisense nucleic acids that enable exon skipping |
CN115666589A (en) | 2020-03-19 | 2023-01-31 | 艾维迪提生物科学公司 | Compositions and methods for treating facioscapulohumeral muscular dystrophy |
US20230285586A1 (en) * | 2020-07-23 | 2023-09-14 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
CA3186755A1 (en) * | 2020-07-23 | 2022-01-27 | Romesh R. Subramanian | Muscle-targeting complexes and uses thereof |
EP4330395A1 (en) | 2021-04-30 | 2024-03-06 | Sarepta Therapeutics, Inc. | Treatment methods for muscular dystrophy |
EP4361269A1 (en) | 2021-06-23 | 2024-05-01 | Nippon Shinyaku Co., Ltd. | Combination of antisense oligomers |
US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
IL309909A (en) * | 2021-07-09 | 2024-03-01 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
IL309911A (en) * | 2021-07-09 | 2024-03-01 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
WO2023026994A1 (en) | 2021-08-21 | 2023-03-02 | 武田薬品工業株式会社 | Human transferrin receptor binding peptide-drug conjugate |
IL311025A (en) | 2021-08-24 | 2024-04-01 | Peptidream Inc | Human transferrin receptor-binding antibody-peptide conjugate |
IL311175A (en) | 2021-09-01 | 2024-04-01 | Biogen Ma Inc | Anti-transferrin receptor antibodies and uses thereof |
CA3231330A1 (en) | 2021-09-16 | 2023-03-23 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
WO2023178230A1 (en) | 2022-03-17 | 2023-09-21 | Sarepta Therapeutics, Inc. | Phosphorodiamidate morpholino oligomer conjugates |
US11931421B2 (en) | 2022-04-15 | 2024-03-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
Family Cites Families (200)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2631173A (en) | 1949-01-04 | 1953-03-10 | Phillips Petroleum Co | Production of cyclooctadiene |
IL54795A (en) | 1978-05-26 | 1980-10-26 | Yeda Res & Dev | Analgesic compositions comprising substituted bicyclic and spiroaliphatic amines and certain novel compounds of these types |
ATE108692T1 (en) | 1988-03-02 | 1994-08-15 | Uab Research Foundation | REVERSIBLE MECHANICAL-CHEMICAL MACHINES MADE OF BIOELASTOMERS CAPABLE OF ADJUSTABLE INVERSE TEMPERATURE TRANSITIONS TO TRANSFORM CHEMICAL WORK INTO MECHANICAL WORK. |
WO1991004753A1 (en) | 1989-10-02 | 1991-04-18 | Cetus Corporation | Conjugates of antisense oligonucleotides and therapeutic uses thereof |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US6255455B1 (en) | 1996-10-11 | 2001-07-03 | The Trustees Of The University Of Pennsylvania | Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
EP1264826B1 (en) | 2000-02-22 | 2005-03-30 | Banyu Pharmaceutical Co., Ltd. | Novel imidazoline compounds |
EP1282699B1 (en) | 2000-05-04 | 2012-11-21 | Sarepta Therapeutics, Inc. | Splice-region antisense composition and method |
EP1191097A1 (en) | 2000-09-21 | 2002-03-27 | Leids Universitair Medisch Centrum | Induction of exon skipping in eukaryotic cells |
JP2002253259A (en) | 2001-03-02 | 2002-09-10 | Bio Applied Systems:Kk | Gene encoding anti-bisphenol a antibody, recombinant protein and method for producing the same |
US20040063654A1 (en) | 2001-11-02 | 2004-04-01 | Davis Mark E. | Methods and compositions for therapeutic use of RNA interference |
US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
EP2284535A1 (en) | 2002-03-11 | 2011-02-16 | Momenta Pharmaceuticals, Inc. | Low molecular weight heparins |
ES2509140T3 (en) | 2002-11-25 | 2014-10-17 | Masafumi Matsuo | ENA nucleic acid drugs that modify splicing in mRNA precursors |
WO2004055164A2 (en) | 2002-12-13 | 2004-07-01 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
AU2003301020A1 (en) | 2002-12-20 | 2004-07-22 | Sankyo Company, Limited | Isoquinolinone derivatives and their use as therapeutic agents |
CA2524255C (en) | 2003-03-21 | 2014-02-11 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
EP2241331A3 (en) | 2003-12-15 | 2011-03-09 | Alexion Pharmaceuticals, Inc. | Novel anti-DC-SIGN antibodies |
WO2005111211A2 (en) | 2004-05-14 | 2005-11-24 | Rosetta Genomics Ltd. | Micronas and uses thereof |
SI2206781T1 (en) | 2004-06-28 | 2016-05-31 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
WO2006022688A1 (en) | 2004-08-06 | 2006-03-02 | Applera Corporation | Diagnosis of pancreatic cancer by using pancreatic targets |
FR2874384B1 (en) | 2004-08-17 | 2010-07-30 | Genethon | ADENO-ASSOCIATED VIRAL VECTOR FOR PRODUCING EXON JUMP IN A GENE ENCODING A PROTEIN WITH DISPENSABLE DOMAINS |
WO2006050262A2 (en) | 2004-11-01 | 2006-05-11 | The Regents Of The University Of California | Compositions and methods for modification of biomolecules |
US8431558B2 (en) | 2004-11-01 | 2013-04-30 | The Regents Of The University Of California | Compositions and methods for modification of biomolecules |
US20120122801A1 (en) | 2005-01-05 | 2012-05-17 | Prosensa B.V. | Mannose-6-phosphate receptor mediated gene transfer into muscle cells |
WO2006091796A2 (en) | 2005-02-22 | 2006-08-31 | Acucela, Inc. | Compositions and methods for diagnosing and treating retinal diseases |
EP2623986B1 (en) | 2006-02-10 | 2017-06-14 | Life Technologies Corporation | Labeling and detection of post translationally modified proteins |
US8859752B2 (en) | 2006-04-18 | 2014-10-14 | The Trustees Of The University Of Pennsylvania | SIRNA-based therapy of Fibrodyplasia Ossificans Progressiva (FOP) |
EP1857548A1 (en) | 2006-05-19 | 2007-11-21 | Academisch Ziekenhuis Leiden | Means and method for inducing exon-skipping |
PT2121751T (en) | 2006-12-08 | 2017-04-18 | Lexicon Pharmaceuticals Inc | Monoclonal antibodies against angptl3 |
EP3330292A1 (en) | 2007-08-21 | 2018-06-06 | Amgen, Inc | Human c-fms antigen binding proteins |
USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
WO2009054725A2 (en) | 2007-10-26 | 2009-04-30 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
EP2119783A1 (en) * | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
WO2009144481A2 (en) | 2008-05-30 | 2009-12-03 | Isis Innovation Limited | Conjugates for delivery of biologically active compounds |
US8084601B2 (en) | 2008-09-11 | 2011-12-27 | Royal Holloway And Bedford New College Royal Holloway, University Of London | Oligomers |
WO2010048586A1 (en) | 2008-10-24 | 2010-04-29 | Avi Biopharma, Inc. | Multiple exon skipping compositions for dmd |
AU2009310557B2 (en) | 2008-10-27 | 2014-09-11 | Academisch Ziekenhuis Leiden | Methods and means for efficient skipping of exon 45 in Duchenne Muscular Dystrophy pre-mRNA |
JP2012524540A (en) | 2009-04-24 | 2012-10-18 | プロセンサ テクノロジーズ ビー.ブイ. | Oligonucleotides containing inosine for treating DMD |
FR2947269B1 (en) | 2009-06-29 | 2013-01-18 | Sanofi Aventis | NEW ANTICANCER COMPOUNDS |
WO2011036640A2 (en) | 2009-09-24 | 2011-03-31 | Cellectis | Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations |
KR102487132B1 (en) | 2009-11-12 | 2023-01-10 | 더 유니버시티 오브 웨스턴 오스트레일리아 | Antisense Molecules and Methods for Treating Pathologies |
WO2011078797A2 (en) | 2009-12-22 | 2011-06-30 | Singapore Health Services Pte. Ltd | Antisense oligonucleotides and uses threreof |
US8734799B2 (en) | 2010-04-13 | 2014-05-27 | The Regents Of The University Of California | Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer |
EP3604264A1 (en) | 2010-04-27 | 2020-02-05 | SynAffix B.V. | Fused cyclooctyne compounds |
KR102095478B1 (en) | 2010-05-28 | 2020-04-01 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups |
IT1400425B1 (en) | 2010-06-08 | 2013-05-31 | Amsterdam Molecular Therapeutics Bv | MODIFIED SNRNAS FOR USE IN THERAPY. |
CA2804185C (en) | 2010-07-12 | 2017-03-21 | Covx Technologies Ireland Limited | Multifunctional antibody conjugates |
TWI541024B (en) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | Antisense nucleic acid |
EP3118316A1 (en) | 2010-09-02 | 2017-01-18 | Université de Mons | Agents useful in treating facioscapulohumeral muscular dystrophy |
ES2631356T3 (en) | 2010-11-30 | 2017-08-30 | F. Hoffmann-La Roche Ag | Low affinity transferrin receptor anti-antibodies and their use to transfer therapeutic scFv through the blood brain barrier |
EA028744B1 (en) | 2010-12-20 | 2017-12-29 | Дженентек, Инк. | Anti-mesothelin antibodies and immunoconjugates |
KR20140052963A (en) | 2011-02-08 | 2014-05-07 | 더 샬롯테-맥클렌버그 하스피털 오쏘러티 디/비/에이 카롤리나스 헬스케어 시스템 | Antisense oligonucleotides |
RU2013143358A (en) | 2011-04-07 | 2015-05-20 | Дженентек, Инк. | ANTI-FGFR4 ANTIBODIES AND WAYS OF THEIR APPLICATION |
US20140193436A1 (en) | 2011-06-24 | 2014-07-10 | Centrose, Llc | Extracellular targeted drug conjugates |
BR112014003999A2 (en) | 2011-08-23 | 2017-06-13 | Roche Glycart Ag | isolated antibody that binds to a near epitope near the human mcsp membrane, isolated nucleic acid, host cell, method of producing an antibody, immunoconjugate, pharmaceutical formulation, use of the antibody, method of treating cancer patients, unduction method of cell lysis in individuals and mcsp immunohistochemical test |
WO2013036748A1 (en) | 2011-09-09 | 2013-03-14 | Berry, Lana, L. | Bicyclo[6.1.0]non-4-yne reagents for chemical modification of oligonucleotides |
CA2858347C (en) | 2011-12-05 | 2020-07-07 | Duke University | V1v2 immunogens |
CA2858576A1 (en) | 2011-12-06 | 2013-06-13 | Research Institute At Nationwide Children's Hospital | Non-ionic, low osmolar contrast agents for delivery of antisense oligonucleotides and treatment of disease |
CA2861247C (en) | 2011-12-28 | 2021-11-16 | Nippon Shinyaku Co., Ltd. | Antisense nucleic acids |
US20130177579A1 (en) | 2012-01-06 | 2013-07-11 | Bioalliance C.V. | Anti-transferrin receptor antibodies and methods using same |
SI2817338T1 (en) | 2012-02-24 | 2017-11-30 | Abbvie Stemcentrx Llc | Dll3 modulators and methods of use |
US9610362B2 (en) | 2012-03-16 | 2017-04-04 | Valerion Therapeutics, Llc | Antisense conjugates for decreasing expression of DMPK |
RS56319B1 (en) | 2012-04-23 | 2017-12-29 | Biomarin Tech Bv | Rna modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders |
JP6460983B2 (en) | 2012-07-03 | 2019-01-30 | バイオマリン テクノロジーズ ベー.フェー. | Oligonucleotides for the treatment of patients with muscular dystrophy |
EP2684892A1 (en) | 2012-07-13 | 2014-01-15 | Association Française contre les Myopathies | Compositions and methods for duchenne muscular dystrophy gene therapy |
EP2895200B1 (en) | 2012-09-14 | 2019-11-06 | Translate Bio MA, Inc. | Multimeric oligonucleotide compounds |
RS64329B1 (en) | 2012-10-23 | 2023-08-31 | Synaffix Bv | Modified antibody, antibody-conjugate and process for the preparation thereof |
ES2701076T3 (en) | 2012-11-24 | 2019-02-20 | Hangzhou Dac Biotech Co Ltd | Hydrophilic linkers and their uses for the conjugation of drugs to molecules that bind to cells |
DK2958944T3 (en) | 2013-02-22 | 2019-06-24 | Abbvie Stemcentrx Llc | ANTI-DLL3 ANTISTOF PBD CONJUGATES AND USES THEREOF |
PL2970964T3 (en) | 2013-03-14 | 2019-06-28 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
CA2906812A1 (en) | 2013-03-15 | 2014-09-18 | Sarepta Therapeutics, Inc. | Improved compositions for treating muscular dystrophy |
JP6612214B2 (en) | 2013-05-20 | 2019-11-27 | ジェネンテック, インコーポレイテッド | Anti-transferrin receptor antibodies and methods of use |
US20160107999A1 (en) | 2013-05-24 | 2016-04-21 | Synaffix B.V. | Substituted azadibenzocyclooctyne compounds and their use in metal-free click reactions |
CN114230675A (en) | 2013-06-05 | 2022-03-25 | 杜克大学 | RNA-guided gene editing and gene regulation |
CA2922544A1 (en) | 2013-08-28 | 2015-03-05 | Stemcentrx, Inc. | Engineered anti-dll3 conjugates and methods of use |
WO2015057065A1 (en) | 2013-10-14 | 2015-04-23 | Synaffix B.V. | Glycoengineered antibody, antibody-conjugate and methods for their preparation |
EP3058083B1 (en) | 2013-10-14 | 2018-04-11 | SynAffix B.V. | Modified glycoprotein, protein-conjugate and process for the preparation thereof |
WO2015073848A1 (en) | 2013-11-14 | 2015-05-21 | Shehadeh Lina A | Methods and compositions employing an osteopontin aptamer to deliver nucleic acids into smooth muscle, endothelial, cardiac and progenitor/stem cells |
EP3097080A1 (en) | 2014-01-24 | 2016-11-30 | SynAffix B.V. | Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne |
JP2017505770A (en) | 2014-01-24 | 2017-02-23 | シンアフィックス ビー.ブイ. | Process for cycloaddition of (hetero) aryl 1,3-dipole compounds with (hetero) cycloalkynes |
AU2015227733B2 (en) | 2014-03-12 | 2019-10-31 | National Center Of Neurology And Psychiatry | Antisense nucleic acids |
AR099625A1 (en) | 2014-03-21 | 2016-08-03 | Lilly Co Eli | IL-21 ANTIBODIES |
JP6750148B2 (en) | 2014-04-25 | 2020-09-02 | 公益財団法人野口研究所 | Process for producing sugar chain cleaving antibody and uniform sugar chain antibody |
TWI713450B (en) | 2014-05-23 | 2020-12-21 | 美商健臻公司 | Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides |
RS59764B1 (en) | 2014-06-17 | 2020-02-28 | Nippon Shinyaku Co Ltd | Antisense nucleic acid for use in the treatment of duchenne's muscular dystrophy |
EP3177633B1 (en) | 2014-08-04 | 2022-07-20 | SynAffix B.V. | Process for the modification of a glycoprotein using a beta-(1,4)-n-acetylgalactosaminyltransferase or a mutant thereof |
JP6733993B2 (en) | 2014-10-03 | 2020-08-05 | シンアフィックス ビー.ブイ. | Sulfamide linker, conjugate of sulfamide linker, and method of preparation |
AU2015346045B2 (en) | 2014-11-14 | 2021-08-26 | Ossianix, Inc. | Variable new antigen receptors (VNARs) directed against transferrin receptor (TfR) and their use |
JP6779876B2 (en) | 2014-11-19 | 2020-11-04 | ジェネンテック, インコーポレイテッド | Anti-transferrin receptor antibody and how to use it |
CA3014641C (en) | 2014-11-21 | 2020-08-18 | Songnian Lin | Insulin receptor partial agonists |
WO2016170186A1 (en) | 2015-04-23 | 2016-10-27 | Synaffix B.V. | PROCESS FOR THE MODIFICATION OF A GLYCOPROTEIN USING A GLYCOSYLTRANSFERASE THAT IS OR IS DERIVED FROM A β(1,4)-N-ACETYLGALACTOSAMINYLTRANSFERASE |
EP4029880A1 (en) | 2015-05-04 | 2022-07-20 | CytomX Therapeutics, Inc. | Activatable anti-cd71 antibodies, and methods of use thereof |
EP4306538A3 (en) | 2015-05-19 | 2024-05-01 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
EP3325509B1 (en) | 2015-07-22 | 2020-12-16 | Inatherys | Anti-tfr antibodies and their use in treating proliferative and inflammatory disorders |
US10144931B2 (en) | 2015-09-15 | 2018-12-04 | Nippon Shinyaku Co., Ltd. | Antisense nucleic acids |
EP3332008A4 (en) | 2015-09-23 | 2019-01-16 | Université Laval | Modification of the dystrophin gene and uses thereof |
MX2018003992A (en) | 2015-10-09 | 2018-08-01 | Wave Life Sciences Ltd | Oligonucleotide compositions and methods thereof. |
EP3858993A1 (en) | 2015-10-09 | 2021-08-04 | Sarepta Therapeutics, Inc. | Compositions and methods for treating duchenne muscular dystrophy and related disorders |
EP4074331A1 (en) | 2015-12-08 | 2022-10-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
FR3044926B1 (en) | 2015-12-09 | 2020-01-31 | Genethon | EFFICIENT GENE THERAPY TOOLS FOR JUMPING DYSTROPHIN EXON 53 |
EP3413922A1 (en) | 2016-02-08 | 2018-12-19 | SynAffix B.V. | Improved sulfamide linkers for use in bioconjugates |
US20210213138A1 (en) | 2016-02-19 | 2021-07-15 | Genisphere Llc | Nucleic Acid Carriers And Therapeutic Methods of Use |
JP7015244B2 (en) | 2016-03-22 | 2022-02-02 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Protease-activated T cell bispecific molecule |
MA45328A (en) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF |
FR3049951A1 (en) | 2016-04-12 | 2017-10-13 | Univ Rabelais Francois | NOVEL PEPTIDE CONSTRUCTS AND THEIR USE IN THE TREATMENT OF TOXOPLASMOSIS |
MA45290A (en) | 2016-05-04 | 2019-03-13 | Wave Life Sciences Ltd | PROCESSES AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS |
WO2017205191A1 (en) | 2016-05-24 | 2017-11-30 | Merck Sharp & Dohme Corp. | Insulin receptor partial agonists and glp-1 analogues |
MA45188A (en) | 2016-06-03 | 2019-04-10 | Wave Life Sciences Ltd | OLIGONUCLEOTIDES, ASSOCIATED COMPOSITIONS AND METHODS |
EP4212176A1 (en) * | 2016-06-20 | 2023-07-19 | Genahead Bio, Inc. | Antibody-drug conjugate |
WO2018007475A1 (en) | 2016-07-05 | 2018-01-11 | Biomarin Technologies B.V. | Pre-mrna splice switching or modulating oligonucleotides comprising bicyclic scaffold moieties, with improved characteristics for the treatment of genetic disorders |
US20190330626A1 (en) * | 2016-07-15 | 2019-10-31 | Ionis Pharmaceuticals, Inc. | Compounds and methods for use in dystrophin transcript |
US20190151476A1 (en) | 2016-07-19 | 2019-05-23 | Duke University | Therapeutic applications of cpf1-based genome editing |
WO2018091544A1 (en) | 2016-11-16 | 2018-05-24 | Biomarin Pharmaceutical, Inc. | Substances for targeting various selected organs or tissues |
US10947540B2 (en) | 2016-11-29 | 2021-03-16 | Association Institut De Myologie | Allele-specific silencing therapy for Dynamin 2-related diseases |
EP3545090A1 (en) | 2016-11-28 | 2019-10-02 | The Board of Regents of The University of Texas System | Prevention of muscular dystrophy by crispr/cpf1-mediated gene editing |
US20190364862A1 (en) | 2016-12-08 | 2019-12-05 | The Board Of Regents Of The University Of Texas System | Dmd reporter models containing humanized duchenne muscular dystrophy mutations |
JOP20190166A1 (en) | 2017-01-05 | 2019-07-02 | Univ Texas | Optimized strategy for exon skipping modifications using crispr/cas9 with triple guide sequences |
MX2019008199A (en) | 2017-01-06 | 2019-11-25 | Avidity Biosciences Llc | Nucleic acid-polypeptide compositions and methods of inducing exon skipping. |
AU2018281280A1 (en) | 2017-06-07 | 2020-01-16 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
MX2020003130A (en) | 2017-09-22 | 2020-09-25 | Avidity Biosciences Inc | Nucleic acid-polypeptide compositions and methods of inducing exon skipping. |
EA201991450A1 (en) | 2017-09-22 | 2019-12-30 | Сарепта Терапьютикс, Инк. | OLIGOMER CONJUGATES FOR EXONISM SKIP IN MUSCULAR DYSTROPHY |
JP2020536060A (en) | 2017-09-28 | 2020-12-10 | サレプタ セラピューティクス, インコーポレイテッド | Combination therapy to treat muscular dystrophy |
MA50753A (en) | 2017-10-04 | 2020-08-12 | Avidity Biosciences Inc | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF |
EP3707155A2 (en) | 2017-11-09 | 2020-09-16 | Vertex Pharmaceuticals Incorporated | Crispr/cas systems for treatment of dmd |
EP3720448A4 (en) | 2017-12-06 | 2021-11-03 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle atrophy and myotonic dystrophy |
US20210095283A1 (en) | 2018-01-04 | 2021-04-01 | Avidity Biosciences, Inc. | Heteroduplex nucleic acid molecules and uses thereof |
EP3735462A1 (en) | 2018-01-05 | 2020-11-11 | The Board of Regents of The University of Texas System | Therapeutic crispr/cas9 compositions and methods of use |
US20200370042A1 (en) | 2018-01-31 | 2020-11-26 | The Board Of Regents Of The University Of Texas System | Compositions and methods for correcting dystrophin mutations in human cardiomyocytes |
CN112040985A (en) | 2018-02-07 | 2020-12-04 | 瑞泽恩制药公司 | Methods and compositions for delivery of therapeutic proteins |
CA3096667A1 (en) | 2018-04-12 | 2019-10-17 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
EP3790968A1 (en) | 2018-05-11 | 2021-03-17 | Alpha Anomeric SAS | Oligonucleotides conjugates comprising 7'-5'-alpha-anomeric-bicyclic sugar nucleosides |
TW202015726A (en) | 2018-05-30 | 2020-05-01 | 瑞士商諾華公司 | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
JP2021526796A (en) | 2018-06-13 | 2021-10-11 | サレプタ セラピューティクス, インコーポレイテッド | Exon skipping oligomer for muscular dystrophy |
US20210261962A1 (en) | 2018-06-21 | 2021-08-26 | The Board Of Regents Of The University Of Texas System | Correction of dystrophin exon 43, exon 45, or exon 52 deletions in duchenne muscular dystrophy |
AU2019314538A1 (en) | 2018-08-02 | 2021-03-11 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
KR20210081324A (en) | 2018-08-02 | 2021-07-01 | 다인 세라퓨틱스, 인크. | Muscle targeting complexes and their use for treating facioscapulohumeral muscular dystrophy |
CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
CA3108328A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating fibrodysplasia ossificans progressiva |
WO2020028842A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating hypertrophic cardiomyopathy |
EA202190421A1 (en) | 2018-08-02 | 2021-06-25 | Дайн Терапьютикс, Инк. | MUSCLE-SPECIFIC COMPLEXES AND THEIR APPLICATION FOR TREATMENT OF MUSCLE ATROPHY |
EP3829649A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof |
US20210322562A1 (en) | 2018-08-02 | 2021-10-21 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating centronuclear myopathy |
US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
EP3830127A4 (en) | 2018-08-02 | 2022-06-29 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating pompe disease |
EA202190419A1 (en) | 2018-08-02 | 2021-06-24 | Дайн Терапьютикс, Инк. | MUSCLE-SPECIFIC COMPLEXES AND THEIR APPLICATION FOR TREATMENT OF FREDREICH'S ATAXIA |
US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
IT201800009682A1 (en) | 2018-10-22 | 2020-04-22 | Ice Spa | CONJUGATES OF BILIARY ACIDS AND THEIR DERIVATIVES FOR THE CARRIAGE OF ACTIVE MOLECULES |
CN113260384A (en) | 2018-11-05 | 2021-08-13 | 西纳福克斯股份有限公司 | Antibody conjugates for targeting TROP-2 expressing tumors |
JP2022513482A (en) | 2018-12-21 | 2022-02-08 | アビディティー バイオサイエンシーズ,インク. | Anti-transferrin receptor antibody and its use |
AU2020263487A1 (en) | 2019-04-25 | 2021-12-16 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
EP3980436A4 (en) | 2019-06-06 | 2023-12-20 | Avidity Biosciences, Inc. | Nucleic acid-polypeptide compositions and uses thereof |
JP2022535911A (en) | 2019-06-06 | 2022-08-10 | アビディティー バイオサイエンシーズ,インク. | UNA amidites and uses thereof |
US20220306685A1 (en) | 2019-06-07 | 2022-09-29 | Dyne Therapeutics, Inc. | Methods of preparing protein-oligonucleotide complexes |
WO2021003573A1 (en) | 2019-07-09 | 2021-01-14 | The Governors Of The University Of Alberta | Exons 45-55 skipping using mutation-tailored cocktails of antisense morpholinos in the dmd gene |
WO2021068761A1 (en) | 2019-10-10 | 2021-04-15 | 苏州亲为药业有限公司 | Humanized monoclonal antibody targeting bcma and having human monkey cross-reactivity |
WO2021076856A1 (en) | 2019-10-18 | 2021-04-22 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
EP4087876A4 (en) | 2020-01-10 | 2024-03-27 | Dyne Therapeutics Inc | Muscle-targeting complexes and uses thereof |
IL294478A (en) | 2020-01-10 | 2022-09-01 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
WO2023283531A2 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health |
WO2021142260A1 (en) | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of acvr1 |
BR112022013603A2 (en) | 2020-01-10 | 2022-09-13 | Dyne Therapeutics Inc | MUSCLE TARGETING COMPLEXES AND USES THEM TO TREAT FACIOSCAPULOUMERAL MUSCULAR DYSTROPHY |
AU2021206234A1 (en) | 2020-01-10 | 2022-09-01 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
CA3163283A1 (en) | 2020-01-10 | 2021-07-15 | Romesh R. Subramanian | Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health |
US20230203180A1 (en) | 2020-01-10 | 2023-06-29 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health |
WO2021142331A1 (en) | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of genes associated with cardiac muscle disease |
WO2021142217A1 (en) | 2020-01-10 | 2021-07-15 | Dyne Thereapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of milck1 |
WO2021142269A1 (en) | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of genes associated with muscle atrophy |
US20230117883A1 (en) | 2020-01-24 | 2023-04-20 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof in treating muscle atrophy |
CA3163290A1 (en) | 2020-01-31 | 2021-08-05 | Romesh R. Subramanian | Anti-transferrin receptor (tfr) antibody and uses thereof |
WO2021154477A1 (en) | 2020-01-31 | 2021-08-05 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (tfr) antibody and uses thereof |
JP2023535443A (en) | 2020-07-23 | 2023-08-17 | ダイン セラピューティクス,インコーポレーテッド | Anti-transferrin receptor (TfR) antibodies and uses thereof |
US20230285586A1 (en) | 2020-07-23 | 2023-09-14 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US20230346966A1 (en) | 2020-07-23 | 2023-11-02 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof in treating muscle atrophy |
JP2023535078A (en) | 2020-07-23 | 2023-08-15 | ダイン セラピューティクス,インコーポレーテッド | Muscle-targeted complexes and their use for treating myotonic dystrophy |
CA3186755A1 (en) | 2020-07-23 | 2022-01-27 | Romesh R. Subramanian | Muscle-targeting complexes and uses thereof |
IL299666A (en) | 2020-07-23 | 2023-03-01 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
EP4208173A1 (en) | 2020-09-03 | 2023-07-12 | Dyne Therapeutics, Inc. | Methods of preparing protein-oligonucleotide complexes |
US20240100177A1 (en) | 2020-12-04 | 2024-03-28 | Dyne Therapeutics, Inc. | Antibody-oligonucleotide complexes and uses thereof |
MX2023007881A (en) | 2020-12-31 | 2023-07-10 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating myotonic dystrophy. |
IL304049A (en) | 2020-12-31 | 2023-08-01 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
EP4359008A2 (en) | 2021-06-21 | 2024-05-01 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating friedreich's ataxia |
WO2022271549A1 (en) | 2021-06-21 | 2022-12-29 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating pompe disease |
IL309911A (en) | 2021-07-09 | 2024-03-01 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
IL309909A (en) | 2021-07-09 | 2024-03-01 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
IL309936A (en) | 2021-07-09 | 2024-03-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for treating dystrophinopathies |
US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
CA3226367A1 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
WO2023283615A1 (en) | 2021-07-09 | 2023-01-12 | Dynetherapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
WO2023283629A1 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations thereof for treating facioscapulohumeral muscular dystrophy |
US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
IL309937A (en) | 2021-07-09 | 2024-03-01 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
KR20240032953A (en) | 2021-07-09 | 2024-03-12 | 다인 세라퓨틱스, 인크. | Muscle targeting complex and its use to treat myotonic dystrophy |
WO2023044398A1 (en) | 2021-09-16 | 2023-03-23 | Dyne Therapeutics, Inc. | Dosing of muscle targeting complexes for treating dystrophinopathies |
AU2022377070A1 (en) | 2021-11-01 | 2024-04-11 | Dyne Therapeutics, Inc. | Muscle targeting complexes for treating dystrophinopathies |
WO2023086864A1 (en) | 2021-11-12 | 2023-05-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes for treating facioscapulohumeral muscular dystrophy |
-
2019
- 2019-08-02 CA CA3108282A patent/CA3108282A1/en active Pending
- 2019-08-02 JP JP2021529254A patent/JP2021532831A/en active Pending
- 2019-08-02 SG SG11202100934PA patent/SG11202100934PA/en unknown
- 2019-08-02 EP EP19844892.0A patent/EP3829595A4/en active Pending
- 2019-08-02 WO PCT/US2019/044949 patent/WO2020028832A1/en active Application Filing
- 2019-08-02 KR KR1020217005988A patent/KR20210081322A/en unknown
- 2019-08-02 AU AU2019312692A patent/AU2019312692A1/en active Pending
- 2019-08-02 US US17/265,024 patent/US20210308273A1/en not_active Abandoned
- 2019-08-02 CN CN201980064966.2A patent/CN112955153A/en active Pending
- 2019-08-02 MX MX2021001281A patent/MX2021001281A/en unknown
-
2021
- 2021-01-31 IL IL280527A patent/IL280527A/en unknown
-
2022
- 2022-01-21 US US17/580,844 patent/US11369689B2/en active Active
- 2022-05-24 US US17/751,875 patent/US11497815B2/en active Active
- 2022-09-08 US US17/930,522 patent/US11633496B2/en active Active
-
2023
- 2023-03-10 US US18/181,623 patent/US11833217B2/en active Active
- 2023-10-24 US US18/492,894 patent/US20240066139A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2021532831A (en) | 2021-12-02 |
AU2019312692A1 (en) | 2021-03-11 |
EP3829595A1 (en) | 2021-06-09 |
US11833217B2 (en) | 2023-12-05 |
US20220288220A1 (en) | 2022-09-15 |
KR20210081322A (en) | 2021-07-01 |
US11633496B2 (en) | 2023-04-25 |
WO2020028832A1 (en) | 2020-02-06 |
US20240066139A1 (en) | 2024-02-29 |
US11497815B2 (en) | 2022-11-15 |
US11369689B2 (en) | 2022-06-28 |
US20220143206A1 (en) | 2022-05-12 |
US20230001002A1 (en) | 2023-01-05 |
US20230270873A1 (en) | 2023-08-31 |
CN112955153A (en) | 2021-06-11 |
MX2021001281A (en) | 2021-07-15 |
EP3829595A4 (en) | 2022-08-24 |
US20210308273A1 (en) | 2021-10-07 |
CA3108282A1 (en) | 2020-02-06 |
IL280527A (en) | 2021-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL280527A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
IL280536A (en) | Muscle targeting complexes and uses thereof | |
IL280426A (en) | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy | |
IL280483A (en) | Muscle targeting complexes and uses thereof for treating pompe disease | |
EP3830130A4 (en) | Muscle targeting complexes and uses thereof for treating centronuclear myopathy | |
IL280535A (en) | Muscle targeting complexes and uses thereof for treating friedreich's ataxia | |
IL299662A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
IL276808A (en) | Compositions and methods for cancer treatment | |
IL267795A (en) | Combination therapy for the treatment of cancer | |
IL309912A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
IL309937A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
IL309911A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
IL309909A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
IL309935A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
GB201903546D0 (en) | Cancer treatment | |
IL287652A (en) | Cancer treatment | |
IL266993A (en) | Combination therapy for the treatment of cancer | |
IL285466A (en) | Cancer treatment | |
ZA202002526B (en) | New alcoxyamino derivatives for treating pain and pain related conditions | |
IL269121A (en) | Usl-311 for use in the treatment of cancer | |
IL288035A (en) | Cancer treatment | |
GB201819920D0 (en) | Cancer treatment | |
IL253642A0 (en) | Combination therapy for the treatment of cancer | |
GB201907204D0 (en) | Cancer treatment 3 | |
GB201907150D0 (en) | Cancer treatment 2 |